COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

New CPTAC Imaging Data Available

New histopathology slides available from CPTAC lung squamous cell carcinoma, lung adenocarcinoma and glioblastoma multiforme studies. 149 images from 28 new cases added in the month of February 2020 are publicly available on the TCIA CPTAC Pathology Portal!


Making Space for Ubiquitin Proteomics

Protein ubiquitylation is best known for its role in degradation, leading molecules to the cell’s recycle bin, but it also has roles in cellular processing and protein interactions.  Unfortunately, research using proteomic techniques have been limited due to experimental and technical complications.    


OCCPR Webinar: The Cancer Imaging Archive

The Cancer Imaging Archive (TCIA) houses radiology and histopathology data for the CPTAC Program.  There are over 1500 cases and with more than 6000 images…and counting…of 10 cancer types freely available for the public to view.  Each case has complementary proteomic data through the Proteomic Data Commons and genomic data through the


New, Detailed Molecular Roadmap Boosts Fight Against Endometrial Cancer

After 12 million measurements, new drug targets emerge


CPTAC Survey Results Show Success

The Office of Cancer Clinical Proteomics Research (OCCPR) cares what you think about the Clinical Proteomic Tumor Analysis Consortium (CPTAC) program and all its offerings! Working with Clarivate Analytics to conduct a survey, we wanted to determine the effect of the CPTAC program on the proteogenomic research community.  The evaluation provided the NCI with an objective, third-party assessment of CPTAC program implementation.


New CPTAC Histopathology Imaging Data Ready to View

The addition of 367 new pathology slides and 51 new pathology subjects for lung squamous cell carcinoma is now available on the TCIA CPTAC Pathology Portal.  Additional imaging data is also available for 10 cancer types including cutaneous melanoma, clear cell renal cell carcinoma, head & neck squamous cell carcinoma, glioblastoma multiforme, lung adenocarcinoma


OCCPR Webinar: Heatmap Visualization Tool for Cancer Research

Visualizing gene and protein expression from comprehensive genomics and proteomics (mass spectrometry generated) data is beneficial for researchers but often difficult to achieve. Researchers from the Mount Sinai PGDAC team within the CPTAC program have developed a new interactive data tool to query genes and proteins of interest in a visual format.


Micro-Scaled Method Holds Promise as Improved Cancer Diagnostic Platform

Using a single-needle biopsy and new technology for tumor diagnosis developed by Baylor College of Medicine and the Broad Institute of MIT and Harvard, researchers have been able to provide a more detailed and wider window into cancer biology, tumor type and the mechanisms of response and resistance to therapy than with conventional approaches.


GDC Release 22 Has GBM Discovery Data

The Genomic Data Commons (GDC) data release 22 is now available and includes data from the CPTAC Glioblastoma Multiforme Discovery Study. 


Request For Proposal - Biospecimen Core Resource

The Clinical Proteomic Tumor Analysis Consortium (CPTAC), sponsored by the National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research (OCCPR) and managed by The Frederick National Laboratory for Cancer Research (FNLCR), is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteomics, genomics and proteogenomics.  


Pages